Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy
Gut and Liver
;
: 102-110, 2018.
Article
in English
| WPRIM
| ID: wpr-739933
ABSTRACT
BACKGROUND/AIMS:
To determine the prognostic value of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 in gallbladder cancer (GBC) during palliative chemotherapy.METHODS:
One hundred and twenty-three patients with pathologically confirmed unresectable GBC were included. Differences in serum CEA and CA 19-9 levels before and after chemotherapy were measured. Receiver operating characteristic curve analysis, Kaplan-Meier analyses of CEA, CA 19-9, and combined changes were performed to assess the optimal cutoff values and survival rates.RESULTS:
Patients with decreased tumor markers had significantly better progression-free survival (PFS) and overall survival (OS) than patients with increased tumor markers. The pre- and postchemotherapy CA 19-9 ratio had the highest area-under-the-curve values for predicting 3-month PFS and 1-year OS. In the multivariate analysis, increases in serum CA 19-9 during palliative chemotherapy in patients with unresectable GBC was an independent prognosticator of poor PFS and OS, with hazard ratios of 2.20 (p=0.001) and 1.67 (p=0.020), respectively. Patients with increases >10-fold were considered to have progressive disease, whereas individuals with increases >3-fold were likely to benefit from early imaging follow-up.CONCLUSIONS:
CA 19-9 kinetics was a reliable prognosticator of PFS and OS in patients with unresectable GBC who underwent palliative chemotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Kinetics
/
Adenocarcinoma
/
Carcinoembryonic Antigen
/
Biomarkers, Tumor
/
Multivariate Analysis
/
Survival Rate
/
ROC Curve
/
Follow-Up Studies
/
Disease-Free Survival
/
CA-19-9 Antigen
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS